Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 2, 2023

Study Completion Date

March 10, 2024

Conditions
GastritisDyspepsiaHelicobacter Pylori InfectionGastric CancerPeptic Ulcer
Interventions
DRUG

Esomeprazole

High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID

DRUG

Amoxicillin

High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID

DRUG

Bismuth

Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

DRUG

Esomeprazole

BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

DRUG

Amoxicillin

Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

DRUG

Clarithromycin

Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

Trial Locations (1)

710032

Xijing Hosipital of Digestive Disease, Xi'an

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER